Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford(Centre for Cancer Biology), Timothy P. Hughes(South Australia Pathology), Wendy T Parker(University of South Australia), Daniel Thomson(South Australia Pathology), Carol Wadham(South Australia Pathology), Joel Geoghegan(Australian Cancer Research Foundation), Nathalie Nataren(South Australia Pathology), Deborah L. White(ANZCHOG), Haley Altamura(South Australia Pathology), Zoe Donaldson(South Australia Pathology), Doris Stangl(South Australia Pathology), Hamish S. Scott(Centre for Cancer Biology), Naranie Shanmuganathan(South Australia Pathology), Nur Hezrin Shahrin(South Australia Pathology), Sa-Hee Park(Leukemia Research Foundation), David M. Ross(South Australia Pathology), Jodi Braley(South Australia Pathology), Justine E. Marum(Victorian Clinical Genetics Services), Christopher N Hahn(South Australia Pathology), Jasmina Georgievski(South Australia Pathology), Anna Brown(South Australia Pathology), Agnes S. M. Yong(South Australia Pathology), Christian Dietz, Adrian Purins(South Australia Pathology), Soohyun Kim(Konkuk University), Paul Wang(South Australia Pathology), Dong-Wook Kim(Leukemia Research Foundation), Jinghua Feng(Australian Cancer Research Foundation), Andreas Schreiber(University of South Australia), Soo-Young Choi(Leukemia Research Foundation), David T Yeung(South Australia Pathology), Martin Mueller, Ieuan Walker(King's College London)
Cited by 208
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464